Vyant Bio, Inc.: insider trades · United States · SEC (Form 4)

About Vyant Bio, Inc.

Vyant Bio, Inc. is a United States-based biotechnology company listed on the NASDAQ under the ticker VYNT. The company’s current corporate identity emerged in March 2021, when Cancer Genetics, Inc. completed a merger with StemoniX and was renamed Vyant Bio, Inc. The transaction repositioned the business toward biotechnology-enabled drug discovery rather than a traditional clinical-stage drug development model. Its principal operating footprint has been associated with Cherry Hill, New Jersey, reflecting a U.S. East Coast headquarters base. ([nasdaq.com](https://www.nasdaq.com/press-release/cancer-genetics-and-stemonix-announce-merger-closing-2021-03-31?utm_source=openai)) Vyant Bio was built around two main operating assets: StemoniX and vivoPharm. StemoniX focused on high-density human iPSC-derived screening platforms, especially neural and cardiac models, designed to improve the predictability of preclinical research and support compound screening, disease modeling, and translational discovery work. vivoPharm contributed preclinical development capabilities and contract research expertise. Together, these businesses positioned Vyant Bio as a technology-enabled discovery platform serving biopharma partners and internal research programs. The company’s scientific emphasis was historically centered on neurology, oncology, and adjacent therapeutic areas where better translational tools can reduce development risk. ([nasdaq.com](https://www.nasdaq.com/press-release/cancer-genetics-and-stemonix-announce-merger-closing-2021-03-31?utm_source=openai)) From a competitive standpoint, Vyant Bio differentiated itself by combining human biology-based models, screening infrastructure, and preclinical services rather than by building a conventional commercial therapeutics portfolio. That positioned the company against contract research organizations, cell-model developers, and drug-discovery platform companies competing on data quality, biological relevance, and speed. For investors, however, the most important point is that the company’s profile has changed materially. In November 2023, Vyant Bio disclosed that it was in winddown mode following the sale of substantially all of its assets and that it expected to pursue dissolution, with any shareholder value dependent on final liquidation proceeds. ([nasdaq.com](https://www.nasdaq.com/press-release/vyant-bio-provides-update-on-winddown-activities-2023-11-10?utm_source=openai)) As a result, recent developments are primarily about restructuring, asset monetization, and corporate exit rather than product launch or commercial expansion. The company’s public-market relevance now lies more in the liquidation process, governance actions, and SEC Form 4 insider transactions than in an active operating growth story. For French-speaking investors evaluating U.S. listed small caps, Vyant Bio should therefore be viewed as an NASDAQ-listed United States biotech whose original drug-discovery platform model has been overtaken by a winddown and dissolution process. ([nasdaq.com](https://www.nasdaq.com/press-release/vyant-bio-provides-update-on-winddown-activities-2023-11-10?utm_source=openai))